InvestorsHub Logo
Post# of 64574
Next 10
Followers 253
Posts 17905
Boards Moderated 0
Alias Born 01/19/2006

Re: IdeasPS post# 26468

Friday, 11/24/2017 12:37:49 PM

Friday, November 24, 2017 12:37:49 PM

Post# of 64574
CPRX: We have LTCGs, 154-591%, in all tranches purchased in 2012-2016 @ > $0.50 ...IMO, it will see higher than current $3.49-$3.50.

Pipeline here:

https://ih.advfn.com/p.php?pid=nmona&article=76140560

"Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS.

Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission. In addition, Catalyst is developing a generic version of Sabril® (vigabatrin)."

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.